drugset / Trial / NCT00343525

Repeat-Dose Study of Bavituximab in Patients With Chronic Hepatitis C

NCT00343525

Phase 1 Completed 24 enrolled Peregrine Pharmaceuticals
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the safety and tolerability of bavituximab when administered via an arm vein as multiple infusions and to examine how bavituximab behaves in the body and how it effects the amount of hepatitis C virus and immune modulators in individuals with chronic infection.

Timeline

Start
2006-05
Primary completion
2007-01
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Bavituximab Monoclonal antibody Intravenous